Acrivon Therapeutics Net Debt Growth & History (ACRV)

Acrivon Therapeutics's net debt was −$38.8M for fiscal 2025.

View full Acrivon Therapeutics company overview

Acrivon Therapeutics annual net debt history

Acrivon Therapeutics annual net debt

Fiscal yearPeriod endedNet debtChangeGrowth
20252025-12-31−$38.8M−$2.6M
20242024-12-31−$36.2M−$4.8M
20232023-12-31−$31.4M−$6.8M
20222022-12-31−$24.6M$69.4M
20212021-12-31−$94.0M

Acrivon Therapeutics net debt trends

Between the periods ended 2021-12-31 and 2025-12-31, Acrivon Therapeutics's net debt increased from −$94.0M to −$38.8M, a change of $55.2M. The latest reported quarter, Q2 2026, shows −$39.3M.

About the metric

What net debt means

Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.

Calculation and source

How net debt is calculated

TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Acrivon Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about ACRV yet. Start the conversation.

Write the first post